{"id":"anecortave","rwe":[{"pmid":"23971874","year":"2013","title":"Update on current and future novel therapies for dry age-related macular degeneration.","finding":"","journal":"Expert review of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"23498916","year":"2013","title":"VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.","finding":"","journal":"Bioorganic & medicinal chemistry","studyType":"Clinical Study"},{"pmid":"23440797","year":"2013","title":"Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"23322580","year":"2013","title":"Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes.","finding":"","journal":"Investigative ophthalmology & visual science","studyType":"Clinical Study"},{"pmid":"23301619","year":"2013","title":"Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen.","finding":"","journal":"ACS chemical biology","studyType":"Clinical Study"}],"tags":[{"label":"anecortave","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Plasminogen activator inhibitor 1","category":"target"},{"label":"SERPINE1","category":"gene"},{"label":"S01LA02","category":"atc"},{"label":"Active","category":"status"},{"label":"Exudative age-related macular degeneration","category":"indication"},{"label":"Angiogenesis Inhibitors","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Growth Inhibitors","category":"pharmacology"},{"label":"Growth Substances","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=anecortave","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:56:27.011292+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:56:32.183376+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=anecortave","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:56:32.538182+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4781942/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:56:33.244888+00:00"}},"allNames":"retaane","offLabel":[],"synonyms":["anecortave acetate","anecortave","retaane"],"timeline":[{"date":"2006-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"brandName":"Retaane","ecosystem":[{"indication":"Exudative age-related macular degeneration","otherDrugs":[{"name":"aflibercept","slug":"aflibercept","company":"Regeneron Pharmaceuticals"},{"name":"brolucizumab","slug":"brolucizumab","company":"Novartis Pharms Corp"},{"name":"faricimab","slug":"faricimab","company":"Genentech Inc"},{"name":"pegaptanib","slug":"pegaptanib","company":"Valeant Pharms Llc"}],"globalPrevalence":900000000}],"mechanism":{"target":"Plasminogen activator inhibitor 1","targets":[{"gene":"SERPINE1","source":"DrugCentral","target":"Plasminogen activator inhibitor 1","protein":"Plasminogen activator inhibitor 1"}],"modality":"Small Molecule","drugClass":"anecortave","explanation":"","oneSentence":"","technicalDetail":"Retaane acts as a competitive inhibitor of plasminogen activator inhibitor 1, preventing its interaction with plasminogen activators and thereby reducing the breakdown of the blood-retina barrier."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/217","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=anecortave","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=anecortave","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:47:48.185602","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:56:34.888092+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"verteporfin","drugSlug":"verteporfin","fdaApproval":"2000-04-12","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"pegaptanib","drugSlug":"pegaptanib","fdaApproval":"2004-12-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ranibizumab","drugSlug":"ranibizumab","fdaApproval":"2006-06-30","relationship":"same-class"},{"drugName":"aflibercept","drugSlug":"aflibercept","fdaApproval":"2011-11-18","relationship":"same-class"},{"drugName":"brolucizumab","drugSlug":"brolucizumab","fdaApproval":"2019-10-07","relationship":"same-class"},{"drugName":"bevacizumab","drugSlug":"bevacizumab","fdaApproval":"2004-02-26","relationship":"same-class"},{"drugName":"faricimab","drugSlug":"faricimab","fdaApproval":"2022-01-28","relationship":"same-class"}],"genericName":"anecortave","indications":{"approved":[{"name":"Exudative age-related macular degeneration","source":"DrugCentral","snomedId":414173003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":900000000,"prevalenceMethod":"curated","prevalenceSource":"Retina, 2018 (PMID:29059101)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"verteporfin","brandName":"verteporfin","genericName":"verteporfin","approvalYear":"2000","relationship":"same-class"},{"drugId":"pegaptanib","brandName":"pegaptanib","genericName":"pegaptanib","approvalYear":"2004","relationship":"same-class"},{"drugId":"ranibizumab","brandName":"ranibizumab","genericName":"ranibizumab","approvalYear":"2006","relationship":"same-class"},{"drugId":"aflibercept","brandName":"aflibercept","genericName":"aflibercept","approvalYear":"2011","relationship":"same-class"},{"drugId":"brolucizumab","brandName":"brolucizumab","genericName":"brolucizumab","approvalYear":"2019","relationship":"same-class"},{"drugId":"bevacizumab","brandName":"bevacizumab","genericName":"bevacizumab","approvalYear":"2004","relationship":"same-class"},{"drugId":"faricimab","brandName":"faricimab","genericName":"faricimab","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00884039","phase":"NA","title":"Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients","status":"TERMINATED","sponsor":"Cornea Research Foundation of America","startDate":"2009-05","conditions":["Transplant","Intraocular Pressure"],"enrollment":7,"completionDate":"2010-09"},{"nctId":"NCT00041483","phase":"PHASE3","title":"Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2002-06","conditions":["Macular Degeneration"],"enrollment":530,"completionDate":"2005-08"},{"nctId":"NCT00065728","phase":"PHASE3","title":"Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2003-06","conditions":["Macular Degeneration"],"enrollment":111,"completionDate":"2008-10"},{"nctId":"NCT00788541","phase":"PHASE2","title":"A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2008-12","conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"enrollment":197,"completionDate":"2009-09"},{"nctId":"NCT00058994","phase":"PHASE3","title":"An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-03","conditions":["Macular Degeneration","Maculopathy, Age-Related"],"enrollment":0,"completionDate":"2006-11"},{"nctId":"NCT00299507","phase":"PHASE3","title":"Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-03","conditions":["Macular Degeneration"],"enrollment":240,"completionDate":"2008-04"},{"nctId":"NCT00691717","phase":"PHASE2,PHASE3","title":"Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-06","conditions":["Open-angle Glaucoma","Oular Hypertension"],"enrollment":201,"completionDate":"2009-09"},{"nctId":"NCT00307398","phase":"PHASE3","title":"Anecortave Acetate Risk-Reduction Trial (AART)","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2004-03","conditions":["Dry AMD"],"enrollment":2596,"completionDate":"2009-01"},{"nctId":"NCT00332657","phase":"PHASE3","title":"Anecortave Acetate Risk Reduction Trial (AART)","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2006-09","conditions":["AMD"],"enrollment":36,"completionDate":"2008-12"},{"nctId":"NCT00451152","phase":"PHASE2","title":"Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":["Open-angle Glaucoma"],"enrollment":89,"completionDate":"2009-07"},{"nctId":"NCT00315640","phase":"PHASE2","title":"Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-12","conditions":["Eye Diseases"],"enrollment":70,"completionDate":"2009-07"},{"nctId":"NCT00333216","phase":"PHASE3","title":"Anecortave Acetate Risk-Reduction Trial (AART)","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2005-05","conditions":["AMD"],"enrollment":24,"completionDate":"2008-12"},{"nctId":"NCT00320203","phase":"PHASE2","title":"Anecortave Acetate in Patients With Open-angle Glaucoma","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-03","conditions":["Open-angle Glaucoma"],"enrollment":86,"completionDate":"2008-01"},{"nctId":"NCT00051129","phase":"PHASE3","title":"Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-01","conditions":["Macular Degeneration","Maculopathy, Age-Related","Age-Related Maculopathies","Age-Related Maculopathy","Maculopathies, Age-Related"],"enrollment":291,"completionDate":"2008-05"},{"nctId":"NCT00489840","phase":"PHASE1,PHASE2","title":"Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2007-05","conditions":["Chronic Central Serous Chorioretinopathy"],"enrollment":5,"completionDate":""},{"nctId":"NCT00211458","phase":"PHASE2","title":"Treatment of Age-Related Macular Degeneration With Anecortave Acetate","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2005-09","conditions":["Macular Degeneration"],"enrollment":0,"completionDate":"2007-09"},{"nctId":"NCT00211432","phase":"PHASE2","title":"Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2008-04","conditions":["Pseudovitellium Detachment","Eye Diseases"],"enrollment":4,"completionDate":"2010-04"},{"nctId":"NCT00211315","phase":"PHASE2","title":"Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2002-03","conditions":["Coat's Disease"],"enrollment":4,"completionDate":"2007-03"},{"nctId":"NCT00211419","phase":"PHASE1","title":"Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"","conditions":["Maculopathy, Age-Related"],"enrollment":0,"completionDate":""},{"nctId":"NCT00570479","phase":"PHASE1","title":"Prophylactic Anecortave Acetate in Patients With a Retisert Implant","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2006-09","conditions":["Uveitis, Posterior","Glaucoma"],"enrollment":12,"completionDate":"2010-03"},{"nctId":"NCT00705770","phase":"PHASE2,PHASE3","title":"A Multi-Dose Study With a Treatment for Open-Angle Glaucoma","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2008-05","conditions":["Open-Angle Glaucoma"],"enrollment":0,"completionDate":"2008-07"},{"nctId":"NCT00346957","phase":"PHASE2","title":"A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Alcon Research","startDate":"1999-04","conditions":["AMD"],"enrollment":128,"completionDate":"2003-04"},{"nctId":"NCT00349739","phase":"","title":"Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate","status":"NO_LONGER_AVAILABLE","sponsor":"University of Iowa","startDate":"2003-01","conditions":["Macular Degeneration"],"enrollment":0,"completionDate":"2008-08"},{"nctId":"NCT00211328","phase":"PHASE2","title":"Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2002-03","conditions":["Idiopathic Perifoveal Telangiectasia"],"enrollment":5,"completionDate":"2007-03"},{"nctId":"NCT00211354","phase":"PHASE2","title":"Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)","status":"WITHDRAWN","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2002-03","conditions":["Retinal Vein Occlusion"],"enrollment":0,"completionDate":"2007-04"},{"nctId":"NCT00346866","phase":"PHASE2","title":"Anecortave Acetate Versus Placebo in AMD Patients Following PDT","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2000-05","conditions":["AMD"],"enrollment":136,"completionDate":"2001-12"},{"nctId":"NCT00533962","phase":"NA","title":"IOP Reduction After Anecortave Acetate Injection in Glaucoma Patients","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2007-08","conditions":["Glaucoma","Intraocular Pressure"],"enrollment":30,"completionDate":""},{"nctId":"NCT00211367","phase":"PHASE2","title":"Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)","status":"TERMINATED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2004-04","conditions":["Eye Injuries"],"enrollment":2,"completionDate":"2007-03"},{"nctId":"NCT00211406","phase":"PHASE1","title":"Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)","status":"TERMINATED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"","conditions":["Diabetic Retinopathy"],"enrollment":0,"completionDate":""},{"nctId":"NCT00211471","phase":"PHASE2","title":"Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).","status":"TERMINATED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2002-03","conditions":["Severe Diabetic Retinopathy","Central Retinal Vein Occlusion","Chronic Inflammation","Infectious Diseases"],"enrollment":0,"completionDate":"2007-05"},{"nctId":"NCT00211484","phase":"PHASE2","title":"Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2003-05","conditions":["Age-Related Macular Degenerations.","Subfoveal Neovascularization."],"enrollment":5,"completionDate":"2007-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"011285","UNII":"R5Y8O51589","CHEBI":"CHEBI:31215","INN_ID":"7747","UMLSCUI":"C1693912","chemblId":"CHEMBL4781942","ChEMBL_ID":"CHEMBL2106613","KEGG_DRUG":"D01733","DRUGBANK_ID":"DB12081","PUBCHEM_CID":"7074810","SECONDARY_CAS_RN":"10184-70-0","MESH_SUPPLEMENTAL_RECORD_UI":"C108424"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":76,"therapeuticAreas":["Ophthalmology"],"atcClassification":{"source":"DrugCentral","atcCode":"S01LA02","allCodes":["S01LA02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2013 Sep","pmid":"23971874","title":"Update on current and future novel therapies for dry age-related macular degeneration.","journal":"Expert review of clinical pharmacology"},{"date":"2013 Apr 15","pmid":"23498916","title":"VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.","journal":"Bioorganic & medicinal chemistry"},{"date":"2013 Jan 31","pmid":"23440797","title":"Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.","journal":"The Cochrane database of systematic reviews"},{"date":"2013 Feb 1","pmid":"23322580","title":"Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes.","journal":"Investigative ophthalmology & visual science"},{"date":"2013 Mar 15","pmid":"23301619","title":"Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen.","journal":"ACS chemical biology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:56:34.888092+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}